In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Advances in genome editing have transformed the development of animal models used to understand human diseases. While transgenic mouse models have broadly ...

Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL ...

The Victorian Heart Hospital and the Victorian Heart Institute have successfully led a first-in-human trial for a breakthrough gene-editing therapy ...

A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...